OR-RADISYS
21.5.2020 09:24:06 CEST | Business Wire | Press release
Radisys® Corporation , a global leader of open telecom solutions, today introduced Connect Open Broadband , a carrier-grade, Tier 1 network-hardened, scalable and secure software-defined Passive Optical Network (PON) distribution based on open standards and web-scale architecture to drive rapid innovation and economies of scale. The disaggregated PON solution gives Communications Service Providers (CSPs) deployment flexibility, scalable network growth, and increased service agility with optimized CapEx and OpEx.
News Highlights
- The demand for high-speed broadband services such as internet, video calling and conferencing, and IPTV has created massive growth in network data usage like never before. As such, CSPs’ networks are increasingly overburdened. Service providers need to optimize their networks to scale service delivery efficiently, while maximizing the opportunity to deliver innovation at a rapid pace.
- Radisys’ Connect Open Broadband offers an intelligent, scalable and secure software-defined PON distribution based on the Open Networking Foundation’s (ONF) SEBA reference platform and enhanced with Radisys innovation. This architecture allows for a seamless introduction of the Broadband Forum’s OB-BAA architecture by conforming to the standard YANG models with the Northbound Interface (NBI).
- The solution disaggregates software from the underlying hardware with open interfaces, enabling faster product innovation cycles. The hardware agnostic solution enables service providers to leverage white-box optical line terminals (OLTs) from an interoperable multi-vendor ecosystem for flexible deployable options.
- Connect Open Broadband, built on cloud-native microservices architecture, allows for the addition of new network functions on demand and delivers a path to automated and simplified network operation. The programmability, automation and deeper network visibility further enables better fault detection, faster service delivery and future-proof network expansions.
- The solution is access network (GPON, XGS-PON, NG-PON2) agnostic and offers flexible deployment options.
“In the digital era where high-bandwidth services and pervasive connectivity are required to meet subscriber expectations, service providers are rethinking how they build their networks to meet demand with optimal performance and value,” said Harris Razak, senior vice president of Broadband Access, Radisys. “Connect Open Broadband is a commercially ready, network-hardened solution that allows service providers to enable rapid innovation through disaggregation and to bring new services to market faster.”
“Radisys has been a Partner Member of ONF for many years and has been one of the most active supply chain members working directly with our operator partners. Radisys has helped drive ONF open reference designs and open source platforms and is among the first to commercialize solutions based on ONF platforms,” said Guru Parulkar, Executive Director, ONF. “Radisys’ Connect Open Broadband combines open architectures, software innovation, and white-box hardware to facilitate service agility.”
“Broadband service providers face increased pressure to deliver innovative services to compete with OTT providers,” said Simon Stanley, Analyst at Large, Heavy Reading. “Open, disaggregated solutions give service providers the flexibility to select best-in-class network elements from a number of vendors in order to intelligently scale their networks and deliver the services their customers demand in a cost-effective manner.”
Resources:
- Solution Brief: Connect Open Broadband Access
- Heavy Reading Webinar: Supercharge Your Fiber Broadband Service, May 21 at 12 pm ET
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com .
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005223/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
